Market Place
Sourcing Support
Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China
17 Nov 2024 //
PR NEWSWIRE
ASH 2024: Ascentage Pharma`s Lisaftoclax Data to Be Presented
06 Nov 2024 //
PR NEWSWIRE
Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis
18 Jun 2024 //
PR NEWSWIRE
Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom`s Cancer
04 Jun 2024 //
PR NEWSWIRE
Ascentage Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax
11 Dec 2023 //
PR NEWSWIRE
Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax
11 Dec 2023 //
PR NEWSWIRE
Ascentage to Present Results from Three Studies of Bcl-2 Inhibitor Lisaftoclax
02 Nov 2023 //
PR NEWSWIRE
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration
15 Oct 2023 //
PR NEWSWIRE
Ascentage Received Clearance from FDA to Proceed with PIII Trial for Lisaftoclax
06 Aug 2023 //
PR NEWSWIRE
Ascentage to Present Data of Bcl-2 Inhibitor Lisaftoclax with BTK Inhibitors
03 Nov 2022 //
PRNEWSWIRE
Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax`s (APG-2575)
07 Jun 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.